Validation of current joint American Academy of Allergy, Asthma & Immunology and American College of Allergy, Asthma and Immunology guidelines for antibody response to the 23-valent pneumococcal vaccine using a population of HIV-infected children

Journal of Allergy and Clinical Immunology

Volumn 118, Issue 6, 2006, Pages 1336-1341

  Kamchaisatian, Wasu ^a   Wanwatsuntikul, Watcharaphong ^a   Sleasman, John W ^a   Tangsinmankong, Nutthapong ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

children; HIV; humoral deficiency; Pneumococcal antibody; polysaccharide vaccine

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PNEUMOCOCCUS VACCINE;

ADOLESCENT; AGE DISTRIBUTION; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; AREA UNDER THE CURVE; ARTICLE; CASE CONTROL STUDY; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMORAL IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOGLOBULIN BLOOD LEVEL; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SEROTYPE; STREPTOCOCCUS INFECTION; VALIDATION STUDY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ANTIBODIES, BACTERIAL; ANTIBODY SPECIFICITY; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; HIV; HUMANS; IMMUNOGLOBULIN G; MALE; PNEUMOCOCCAL VACCINES; PRACTICE GUIDELINES; ROC CURVE; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 33845217428     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2006.09.036     Document Type: Article

References (29)

1. Bonilla F.A., Bernstein I.L., Khan D.A., Ballas Z.K., Chinen J., Frank M.M., et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 94 (2005) S1-S63
2. Tangsinmankong N., Bahna S.L., and Good R.A. The immunologic workup of the child suspected of immunodeficiency. Ann Allergy Asthma Immunol 87 (2001) 362-369 quiz 370, 423
3. Primary immunodeficiency diseases: report of an IUIS Scientific Committee. International Union of Immunological Societies. Clin Exp Immunol 118 suppl 1 (1999) 1-28
4. Wasserman R.L., and Sorensen R.U. Evaluating children with respiratory tract infections: the role of immunization with bacterial polysaccharide vaccine. Pediatr Infect Dis J 18 (1999) 157-163
5. Sorensen R.U., and Moore C. Antibody deficiency syndromes. Pediatr Clin North Am 47 (2000) 1225-1252
6. Fleisher T.A., and Oliveira J.B. Functional and molecular evaluation of lymphocytes. J Allergy Clin Immunol 114 (2004) 227-234 quiz 235
7. MacDonald N.E., Halperin S.A., Law B.J., Forrest B., Danzig L.E., and Granoff D.M. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA 280 (1998) 1685-1689
8. Go E.S., and Ballas Z.K. Anti-pneumococcal antibody response in normal subjects: a meta-analysis. J Allergy Clin Immunol 98 (1996) 205-215
9. Lane H.C., Masur H., Edgar L.C., Whalen G., Rook A.H., and Fauci A.S. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med 309 (1983) 453-458
10. Pahwa S.G., Quilop M.T., Lange M., Pahwa R.N., and Grieco M.H. Defective B-lymphocyte function in homosexual men in relation to the acquired immunodeficiency syndrome. Ann Intern Med 101 (1984) 757-763
11. Bernstein L.J., Ochs H.D., Wedgwood R.J., and Rubinstein A. Defective humoral immunity in pediatric acquired immune deficiency syndrome. J Pediatr 107 (1985) 352-357
12. Ballet J.J., Sulcebe G., Couderc L.J., Danon F., Rabian C., Lathrop M., et al. Impaired anti-pneumococcal antibody response in patients with AIDS-related persistent generalized lymphadenopathy. Clin Exp Immunol 68 (1987) 479-487
13. Steinhoff M.C., Auerbach B.S., Nelson K.E., Vlahov D., Becker R.L., Graham N.M., et al. Antibody responses to Haemophilus influenzae type B vaccines in men with human immunodeficiency virus infection. N Engl J Med 325 (1991) 1837-1842
14. Conge A.M., Tarte K., Reynes J., Segondy M., Gerfaux J., Zembala M., et al. Impairment of B-lymphocyte differentiation induced by dual triggering of the B-cell antigen receptor and CD40 in advanced HIV-1-disease. AIDS 12 (1998) 1437-1449
15. Sleasman J.W., and Goodenow M.M. HIV-1 infection. J Allergy Clin Immunol 111 (2003) S582-S592
16. French N., Nakiyingi J., Carpenter L.M., Lugada E., Watera C., Moi K., et al. 23-Valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 355 (2000) 2106-2111
17. Lopez-Palomo C., Martin-Zamorano M., Benitez E., Fernandez-Gutierrez C., Guerrero F., Rodriguez-Iglesias M., et al. Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination. J Med Virol 72 (2004) 517-524
18. Arpadi S.M., Back S., O'Brien J., and Janoff E.N. Antibodies to pneumococcal capsular polysaccharides in children with human immunodeficiency virus infection given polyvalent pneumococcal vaccine. J Pediatr 125 (1994) 77-79
19. Tangsinmankong N., Kamchaisatian W., Day N.K., Sleasman J.W., and Emmanuel P.J. Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in children with human immunodeficiency virus undergoing highly active antiretroviral therapy. Ann Allergy Asthma Immunol 92 (2004) 558-564
20. Concepcion N.F., and Frasch C.E. Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 8 (2001) 266-272
21. Dworkin M.S., Ward J.W., Hanson D.L., Jones J.L., and Kaplan J.E. Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. Clin Infect Dis 32 (2001) 794-800
22. Chiappini E., Galli L., Tovo P.A., Gabiano C., and de Martino M. Persistently high IgA serum levels are a marker of immunological or virological failure of combined antiretroviral therapy in children with perinatal HIV-1 infection. Clin Exp Immunol 140 (2005) 320-324
23. Shearer W.T., Easley K.A., Goldfarb J., Rosenblatt H.M., Jenson H.B., Kovacs A., et al. Prospective 5-year study of peripheral blood CD4, CD8, and CD19/CD20 lymphocytes and serum Igs in children born to HIV-1 women. The P(2)C(2) HIV Study Group. J Allergy Clin Immunol 106 (2000) 559-566
24. Landesman S.H., and Schiffman G. Assessment of the antibody response to pneumococcal vaccine in high-risk populations. Rev Infect Dis 3 suppl (1981) S184-S197
25. Hedlund J., Ortqvist A., Konradsen H.B., and Kalin M. Recurrence of pneumonia in relation to the antibody response after pneumococcal vaccination in middle-aged and elderly adults. Scand J Infect Dis 32 (2000) 281-286
26. Lawrence E.M., Edwards K.M., Schiffman G., Thompson J.M., Vaughn W.K., and Wright P.F. Pneumococcal vaccine in normal children. Primary and secondary vaccination. Am J Dis Child 137 (1983) 846-850
27. American Academy of Pediatrics. Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics 106 (2000) 362-366
28. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348 (2003) 1737-1746
29. Breiman R.F., Keller D.W., Phelan M.A., Sniadack D.H., Stephens D.S., Rimland D., et al. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. Arch Intern Med 160 (2000) 2633-2638